PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Announces First Quarter 2015 Financial Results
PDL BioPharma to Announce First Quarter 2015 Financial Results on May 6, 2015
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note
PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit